Parent AE cytotoxicity limits in one cell panel
Cell-based study · MOLT-4, OVCAR-3, MCF-7, SKOV-3 and NAR [1]
The parent aloe-emodin comparator did not reach the reported 50% XTT viability threshold within the tabulated bounds after 24 h: IC50 >20 μM in four lines and >100 μM in NAR. This is one cell-panel design, not five independent studies.
| Endpoint | Reported result | Reference |
|---|---|---|
| MOLT-4 viability | IC50 >20 μM | [1] |
| OVCAR-3 viability | IC50 >20 μM | [1] |
| MCF-7 viability | IC50 >20 μM | [1] |
| SKOV-3 viability | IC50 >20 μM | [1] |
| NAR viability | IC50 >100 μM | [1] |
Literature-Reported Treatment Conditions
- Exposure duration
- 24 h
- Method
- XTT cytotoxicity panel
- Co-treatment
- Aloe-emodin alone; doxorubicin and synthetic glycosides were separate comparator treatments.
- Reported limits
- Full concentration grid, vehicle and parent purity not established in inspected sections. The IC50 limits are assay endpoints, not treatment concentrations or recommended doses.
Methods and source locations
Compound reported in the paper: Aloe-emodin; Compound label in the paper: AE
Literature compound evidence only; no Adooq lot validation.
Figure 1; Table 1 AE row and footnote a; SI sections 1 and 3
MOLT-4 viability: XTT; untreated-cell OD normalization; each concentration in triplicate, experiment performed three times. — Table 1 AE row, MOLT-4 column; SI section 3 (PDF pp10–11)
OVCAR-3 viability: XTT; untreated-cell OD normalization; each concentration in triplicate, experiment performed three times. — Table 1 AE row, OVCAR-3 column; SI section 3 (PDF pp10–11)
MCF-7 viability: XTT; untreated-cell OD normalization; each concentration in triplicate, experiment performed three times. — Table 1 AE row, MCF-7 column; SI section 3 (PDF pp10–11)
SKOV-3 viability: XTT; untreated-cell OD normalization; each concentration in triplicate, experiment performed three times. — Table 1 AE row, SKOV-3 column; SI section 3 (PDF pp10–11)
NAR viability: XTT; untreated-cell OD normalization; each concentration in triplicate, experiment performed three times. — Table 1 AE row, NAR column; SI section 3 (PDF pp10–11)